MetaCap

Phio Pharmaceuticals (PHIO) vs Palatin Technologies (PTN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Phio Pharmaceuticals (PHIO) has outperformed Palatin Technologies (PTN) over the past year, losing 41.4% versus a loss of 79.9%. Over five years, PTN leads with a -99.3% price change compared with -99.6% for PHIO. Palatin Technologies is the larger company by market cap ($8.2 million vs $7.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PHIO-41.43%PTN-79.93%
+54%-16%-86%
Nov 21, 20251 yearNov 20, 2026
PHIO-99.56%PTN-98.98%
+80%-14%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PHIO versus PTN key metrics
MetricPHIOPTN
Share price$0.656$4.58
Market cap$7.84M$8.16M
1-day change-8.25%-7.10%
YTD return-37.52%-70.22%
1-year return-41.43%-79.93%
5-year return-99.56%-99.35%
EPS (TTM)$-1.21$-2.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$8.83M
Net income (latest FY)$-8.70M$-8.38M
Operating margin—-98.17%
Net margin—-94.88%
52-week high$1.88$31.00
52-week low$0.6395$4.51
Distance from 52-week high-65.11%-85.23%
Analyst consensusnonestrong_buy
Avg. price target upside+2034.15%+1068.12%
Average volume106.09K71.93K
Shares outstanding11.95M1.78M
Employees625
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PHIO has outperformed PTN by 38.5 percentage points over the past year.

About Phio Pharmaceuticals

PHIO stock →

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Palatin Technologies

PTN stock →

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

PHIO vs PTN FAQ

Which is bigger, Phio Pharmaceuticals or Palatin Technologies?

Palatin Technologies (PTN) is larger, with a market capitalization of $8.16M compared with $7.84M for Phio Pharmaceuticals (PHIO).

Which stock has performed better over the past year, PHIO or PTN?

PHIO returned -41.43% over the past 12 months, compared with -79.93% for PTN (price return, excluding dividends). Past performance does not predict future results.

Are Phio Pharmaceuticals and Palatin Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons